title: At the dawn of a new era in treating angina pectoris, or just another antianginal drug? Some considerations about ranolazine.
abstract: Ranolazine is a new compound that has been approved by the FDA for use in patients who have chronic stable angina refractory to conventional antianginal medications. Ranolazine proved to be effective also as monotherapy in patients with stable angina and as part of a combination regimen. This review is inspired by the presentation that legendary figures in contemporary cardiology, such as Braunwald, Komajda and Camm made recently at the Congress of the European Society of Cardiology held in Stockholm, Sweden, last September.
authors.affiliation: "Carol Davila" University of Medicine and Pharmacy, Medical Clinic, Clinical Emergency Hospital Ilfov County, Bucharest, Romania. drhoriabalan@yahoo.com
authors.forename: H
authors.initials: H
authors.lastname: Bălan
mesh_terms: D000083:Acetanilides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D010879:Piperazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000069458:Ranolazine; D055502:Secondary Prevention
chemical_list: D000083:Acetanilides; D004791:Enzyme Inhibitors; D010879:Piperazines; D000069458:Ranolazine